


# Corporate credentials for Life Sciences & Healthcare

January 2024



Helping you  
succeed in  
tomorrow's  
world.

## Our expertise | Life Sciences & Healthcare

### An integrated international approach


Osborne Clarke has an integrated team of experts who understand the technical and legal issues facing the life sciences and healthcare sector in Europe and beyond.

Combining our global reach and knowledge, we support clients in the pharma, biotech and medtech sectors based in multiple jurisdictions throughout the product lifecycle.

We have a track record of helping clients achieve domestic and cross-border mergers and acquisitions, as well as advising on equity and debt fundraisings.

Not only does the team understand the technical and legal issues, but several members also have advanced scientific qualifications and industry experience.

Our expertise, experience and scale means that we are able to give you legal advice that is focused on helping you achieve your business objectives.



### Pharmaceuticals



### Digital Health



### Biotech



### Medtech

### We provide the full range of legal advice, providing commercial and practical solutions:

- Banking and finance
- Commercial
- Competition, antitrust and trade
- Corporate
- Dispute resolution
- ESG
- Employment and pensions
- Infrastructure services
- Intellectual property
- IT and data
- Real estate
- Regulatory and compliance
- Tax

## Our expertise | Venture/growth and M&A

We are one of Europe's most active mid-market transactional corporate teams, renowned for our work in the Life Sciences & Healthcare sector. We act for clients on transactions across the full investment lifecycle.

We have a genuine understanding and enthusiasm for the European venture and growth capital investment market, advising companies and investors on more than 400 European fundraisings a year.

Our international corporate practice consists of 400+ lawyers, extending across the UK (236), Belgium (12), Germany (61), France (16), Spain (28), the Netherlands (15), Sweden (5), Poland (9), Italy (14). We also have corporate legal capability in China, Singapore, the US and India\*. We work as a team to provide our client with a cohesive international corporate practice which looks and feels the same for clients wherever they are.

Our experience in regularly advising on initial and follow-on venture capital financings means we understand the issues and dynamics which regularly arise between a company and its investors in such arrangements. We act for companies and their management teams, as well as investors, at all stages of a company's life-cycle and so understand the process from all sides.

We have the capability, resources and experience to manage transactions efficiently and quickly – whether in Europe, the UK, the US or cross border. We can assist with private equity transactions, equity and debt fundraisings, joint ventures, MBOs/MBIs, exits, acquisition and/or IPOs.

We take an holistic approach to advising on transactions and operate client teams that offer legal advice in areas that we anticipate will be central to your transactions and your business objectives. We have built our knowledge through working with a wide range of clients from the newest "disrupters" to established businesses. This knowledge will be translated for you into practical, real-life advice.


We use our extensive understanding of market norms to help our clients to achieve the best results possible. Our clients include start-ups, global market leaders, angel investors, venture debt providers and more than 50 institutional VC/growth capital investors on venture matters at all stages of the fundraising spectrum, from "seed" rounds through "series A", "series B" and beyond to larger growth capital rounds, as well as convertibles, secondaries and share capital "re-sets".

Our advice to investors includes:

- Fund establishment and ongoing advice
- Investment documentation
- Convertible loans and advance subscriptions
- Due diligence
- Tax advice
- Project management and technology

### OC Ventures

OC Ventures is Osborne Clarke's international resource centre for those driving innovation. It brings together our deep specialist legal and sector expertise, guidance and support to businesses, entrepreneurs and investors in the ventures ecosystem. We support the most exciting emerging technologies, advising from start-up through venture financing and the growth journey beyond, whether continuing to sale, IPO or international expansion. See more information [here](#).



## Our expertise | Specialist support

As a full-service specialised Life Science law firm, we're able to support our company clients not only during their transaction, but also beyond. In particular, we draw on the expertise of colleagues across the firm to support on the following areas:

### Tax

Our team of tax specialists can help resolve all manner of taxation issues, from investment funds, corporate transactions and property tax, right through to employee and expatriate services, share option arrangement, subsidies and VAT. Our simple aim is to help our clients pay their fair share, in a compliant way. But tax can be a complex subject. That's why we make sure that our advice is clear, practical and understandable.

### Commercial

Our experience, commercial focus and sector knowledge means that we routinely produce and advise on contracts which underpin your business. This includes agency and distribution network agreements, outsourcing agreements, consultancy arrangements, licensing, partnerships, joint ventures and sales or enter relevant contract types.

### Regulatory and compliance

Our regulatory practice supports life science clients throughout their road-to-market strategy, addressing any compliance queries. Our advice regularly includes:

- **Advisory work:** Project-specific and regulatory strategy advice; Materials review; Cross-border coordination and international project management
- **Licenses, contacts and procedures:** Legal support with regulatory submissions; Intra-group procedures and policies; Contract drafting throughout product lifecycle; Quality assurance (QA) and regulatory affairs (RA) contracts; Compliance agreements
- **Disputes and investigations:** Regulatory inspections (GxP, advertising, compliance, (pharmaco) vigilance) and interactions with authorities; Audits or investigations by and disputes against regulators and conformity assessment bodies; Competitor disputes on regulatory matters
- **Training:** Client-specific training courses and workshops for in-house teams; Industry modules on regulatory 'hot topics'
- **Lobbying support:** Local and EU regulations drafting, negotiations and legislative procedures; Advice on communications and PR; Legal assistance managing media and journalists; Regulatory support to clients' GA and PA teams

### Data protection

Our data protection team advises on all data protection, security, cyber and privacy related issues, from the implications of EU legislation to international data transfers to day-to-day compliance issues and dealing with requests from the ICO and other data protection regulators. Above all, we can help you take advantage of the growing number of opportunities around data, helping them commercialise it compliantly.


### Intellectual property

Increasingly, intellectual property is the most valuable asset many life science companies hold. Managing, protecting and exploiting your IP is a complex but necessary process. Our all-round experience means that we can help clients from start to finish, so whether you are looking to register a new patent, negotiate licences, sell your IP portfolio or anything in between, we can help. We advise on the tensions between competition rules and IP to make sure you are on the right side of the regulators, while our tax specialists will ensure that your assets are managed in the most efficient way, from cradle to grave.

### Employment

In any transaction often people are your greatest asset and your greatest liability. The employment team specialises in ensuring that risks and liabilities in this area are anticipated and dealt with before they become a problem. From corporate housekeeping, such as ensuring that service contracts are fit for purpose and that your key individuals are properly anchored to the company, to the higher profile employee relation issues that can arise along the way.

Our team also works closely with a dedicated pension and employee incentives team.



## Examples of our VC and M&A experience | Belgium



### VC investments

- Advising **Sunrise**, on its Series B investment round led by Kurma Partners and extended round involving Amazon Alexa Fund and Majycc Innovation Santé – UI investment fund
- Advising **NeGIO Therapeutics** on its €30 million series A investment round
- Advising **OncoDNA** with its €22 million Series B equity financing round and subsequent financings
- Advising **Takeda Ventures**, the US-based VC arm of Takeda Pharmaceutical, on the Series A investment round of Univercells, an innovative bio manufacturing business based in Belgium
- Advising **Apitope** on its €12 million series B financing round
- Advising **BePharBel Manufacturing** on its €6 million capital increase
- Advising **ImmunXpert** on its Series B financing
- Advising **Bio-Sourcing** on its financing round
- Advising **AuXin Surgery** on its €4.2 million series B financing
- Advising **Shire** on its participation in Promethera Biosciences
- Advising **Gilde Healthcare** as lead investor on the €18 million series B investment in Nyxoah
- Advising **Gilde Healthcare and Wellington Partners** as co-leads on the contemplated €20 million series B investment in a Belgian clinical-stage biopharmaceutical company
- Advising **Vesale Pharma** on its fundraising

### M&A and ECM transactions

- Advising **Carlyle** in the current discussions around a deal that would see Carlyle acquire a substantial 65% stake in Medtronic's Patient Monitoring and Respiratory Interventions business, valued at over \$7 billion
- Advising **Sunrise** on the acquisition of assets from Dreem health located in France and the US
- Advising **Vesale Pharma** on the acquisition of some of the activities of Vesale BioSciences
- Advising **Bone Therapeutics** on the sale of their manufacturing facility to Catalent and reversed merger with Medsenic
- Advising **SCTS** and **Delphi Genetics** on their sale to Catalent
- Advising the **Adecco Group** on its acquisition of CMAST
- Advising **OncoDNA** on their friendly takeover bid on IntegraGen
- Advising **ImmunXperts** on their acquisition by US-based Nexelis, a portfolio company of Ampers and Capital Partners
- Advising **TiGenix**, a biopharmaceutical company listed on Euronext Brussels, on various private placements of shares and convertible bonds structured as an ABB or a PIPE
- Advising **TiGenix** on its Nasdaq IPO, raising approximately \$35.6 million
- Advising a **Belgian biotech** on its ongoing IPO preparations on Alternext
- Advising **Gilde Healthcare** as investor in connection with the IPO of Nyxoah
- Advising **TiGenix** on the successful €520 million public takeover bid by Takeda Pharmaceutical
- Advising **Bone Therapeutics/BioSenic** on various private placement of shares and convertible bonds
- Advising **Modis Life Sciences** on the restructuring of their Belgian operations and transfer of assets
- Advising **Visiomed** on the Belgian law aspects of its acquisition of a cosmetics business unit from Omega Pharma
- Advising **Alpha Foods** with the sale of its food supplements business to Vendis Capital

## Examples of our experience | France

### VC investments

- Advising **Hadean Ventures** and **Sunstone Life Science Ventures** on their investment in Step Pharma, a biotechnology company focused on the development of a new class of CTPS1-targeted nucleotide synthesis inhibitors
- Advising **TriCares**, a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve disease on a bridge financing by existing investors and ESOP scheme
- Advising **Terumo Corporation**, a global leader in medical technology listed and headquartered in Japan, in a comprehensive strategic partnership agreement with the French company Diabeloop (a pioneer in AID system for insulin-dependent diabetes management), including investment in a new financing round (Series C) in the amount of circa. €70m alongside existing investors, LBO France and Roche.
- Advising **TriCares** on a €22m B round lead by Wellington Partners, Andera Partners and BioMed Partners

### M&A and ECM transactions

- Advising **Bio-Sourcing** in the acquisition of assets (including patent portfolio and vaccine strains) from Vitam Fero (animal health – vaccines R&D).
- Advising **Air Liquide** on the disposal of Laboratoires Anios (disinfection products and medical device ) to Ardian PE
- Advising **OncoDNA**, a company specializing in precision medicine for the treatment of cancer and other genetic diseases on the acquisition of the French company Integragen listed on Euronext Growth.
- Advising **Bone Therapeutics** (now BioSenic), a bone cell therapy company specializing in addressing unmet medical needs in the field of orthopaedics and bone diseases, in its merger with the French company Medsenic.
- On-going assistance to **Grifols**, a leading global healthcare company listed in Spain, that develops plasma-derived medicines and other innovative biopharmaceutical solutions, on corporate matters, corporate reorganisation and M&A projects since 2014.
- Advsing **Grifols** on the agreement with the Hong Kong's Tiancheng International Investment Ltd. to acquire 100% of the shares of Tiancheng Pharmaceutical Holdings AG, which holds approximately a stake of 89.88% of Biotest ordinary shares and 1.08% of Biotest preferred shares for approximately EUR1.1bn.

## Examples of our experience | Germany



### VC investments

- Advising **Redstone** on its investment in healthcare platform Careloop. Careloop secured EUR 2 million in its recent seed funding round.
- Advising Berlin-based cannabis pharmaceutical and consumer health **Sanity Group** on the USD 3.5 million investment of Snoop Dogg's Casa Verde Capital. The round was presented as a follow-on investment to the company's USD 45 million Series A round announced in June of this year.
- Advising **MA Ventures** on its investment in Lykon. HealthTech startup Lykon has raised EUR 6.4 million in its Pre-Series A funding round.

### M&A and ECM transactions

- Advising a **Digital Health Platform** in the context of the acquisition of DGG (Digital Health Group incl. medulife and DITG) from the founder and GF including advice on subsequent various post-M&A disputes.
- Advising **KMS Klinik Management Systeme** on the sale of the shares of KMS Vertrieb und Services AG and the software "eisTik" to CompuGroup Medical.
- Advising **Sylphar** and **Karo Pharma** on the acquisition of the Satin Naturel business from Del Decus Enterprises Ltd.
- Advising **VAMED Gesundheit Holding Deutschland** on an acquisition in the outpatient division.
- Advising **PharmaDrug, Inc.** (Toronto, Canada) on its sale of all outstanding shares in Pharmadrug Production GmbH, the company's wholly-owned German subsidiary, to Khiron Life Sciences Corp. (Vancouver, Canada).
- Advsing **Grifols** on the agreement with the Hong Kong's Tiancheng International Investment Ltd. to acquire 100% of the shares of Tiancheng Pharmaceutical Holdings AG, which holds approximately a stake of 89.88% of Biotest ordinary shares and 1.08% of Biotest preferred shares for approximately EUR1.1bn.

## Examples of our experience | Italy

### VC investments

- Advising **King's College London / Heqet Therapeutics** on an €8 million Series A funding round to complete its RNA-based therapy program for cardiac regeneration.
- Advising a **multinational company in the dental sector** on a corporate restructuring, providing for the transfer of a business to a newly established company by means of a capital increase in kind with the transfer of the branch. Assisting on all aspects of the restructuring, preparing, inter alia, the related corporate documents, assisting with due diligence relating to contracts and other assets to be transferred, managing the transfer of contracts with public authorities and open tender procedures, advising on the trade union consultation, and other issues connected with the transfer, including a privacy assessment regarding patient consent.
- Advising a **leading multinational medical device company** throughout all stages of its acquisition of 100% of the share capital of the Italian branch of a global company that supplies plasma protein medicinal products and biotherapeutic drugs
- Advising **international medical devices company** in a vendor due diligence for the divestment of several companies under the client's brand specialized in continence care.
- Advising a **leading multinational pharmaceutical company** on the closure, demolition, and potential sale of the real estate associated with a pharmaceuticals production plant; and, on the transfer of a pharmaceutical production facility.
- Advising a **European venture capital fund** with health tech-specific expertise – on an investment into a remote healthcare specialist company.
- Advising **King's College London / Heqet Therapeutics** on an €8 million Series A funding round to complete its RNA-based therapy program for cardiac regeneration.
- Advising the sellers on the acquisition of **Dottori.it** by **Doctolib**, leader on the European market for digital health.
- Advising **Grifols Italia** on the acquisition of the diagnostics division of Novartis Vaccine Diagnostics.
- Advising **Cambrooke Therapeutics** on the acquisition of an Italian distributor of medical / nutritional products, Quaris.

### M&A and ECM transactions

- Advising **Cambrooke Therapeutics** on the acquisition of an Italian distributor of medical / nutritional products, Quaris.
- Advising **Grifols Italy** on the acquisition of the diagnostics division of Novartis Vaccine Diagnostics
- Advising **Dottori.it** on the acquisition of dottori.it by Doctolib, leader on the European market for digital health
- Advising an **US dental medtech business** on a corporate restructuring / transfer of a business to a newly established company by means of a capital increase in kind with the transfer of a branch
- Advising on vendor due diligence for the sale of a group of companies commercialising devices, on behalf of an **US dental equipment manufacturer and dental consumables producer**
- Advsing **Grifols** on the agreement with the Hong Kong's Tiancheng International Investment Ltd. to acquire 100% of the shares of Tiancheng Pharmaceutical Holdings AG, which holds approximately a stake of 89.88% of Biotest ordinary shares and 1.08% of Biotest preferred shares for approximately EUR1.1bn.

## Examples of our experience | Netherlands

### VC investments

- Advising **Sound Bioventures** in a Series B2 financing round for VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation
- Advising the syndicate of **Gilde Healthcare and Ysios** as lead investors and investors **Novartis, Lightstone and NEA** in the EUR 60 million Series A financing round of Tagworks Pharmaceuticals B.V.
- Advising the syndicate of investors consisting of lead investors **Ysios Capital** and **EQT Life Science (formerly LSP)** and including **Inkef** and **Lundback** on VarmX's Series B financing round
- Advising **Vitestro Holding B.V.** in its EUR 12 million Series A Financing Round led by California based investor Sonder Capital Advisors, LLC, alongside existing investors
- Advising lead investors **Ysios Capital and Forbion Growth** on Northsea Therapeutics' USD 80 million Series C financing round
- Advising **iOnctura** in respect of its EUR 20.1 million series A financing round lead by Inkef Capital, VI Partners and Schroder AdvEq, M Ventures and 3B Future Health Fund
- Assisted **Koa Health** in the extension of the EUR 30 mio Series A financing round by **Wellington** and **Ancora** and other investors
- Advising **Lava Therapeutics** on the USD 83 million financing round co led by Novo Ventures and Sanofi Venturesw and Redmile Group, Ysios Capital and BB Pureos Bioventures and existing investors Gilde Healthcare, Versant and MRL Ventures
- Advising **Gilde Healthcare, Versant and MRL Ventures** in respect of the Series B financing round of Lava Therapeutics
- Advising **DSM Venturing** in the financing round of NC Biomatrix

### M&A and ECM transactions

- Advising the shareholders of **Genome Diagnostics B.V. (GenDx)**, a leading HLA diagnostics company, in the competitive auction process relating to the sale of GenDx to Eurobio Scientific for an amount of €135 million
- Advising the shareholders of **MILabs**, providing leading-edge In-Vivo imaging devices through a controlled sale process to Rigaku Corporation
- Advising management on the sale of **Viroclinics-DDL** by Summit Partners to Cerba Healthcare
- Advising **Breath Therapeutics** and existing shareholders Gimv, Sofinnova Partners, Gilde Healthcare and founders on the sale of Breath Therapeutics to Zambon for up to a total of €500 million
- Advising **DSM Venturing, Van Herk Ventures, I2S, Limburgs Instituut voor Ontwikkeling en Financiering and Limburg Ventures** in the sale of Isobionics to BASF. Isobionics is an innovation leader in biotechnology which is serving the global market for natural flavours and fragrances, with a focus on citrus oil components such as nootkatone and valencene
- Advising **INKEF Capital, Gilde Healthcare, Thuja Capital Healthcare, Health Innovation Fund, Van Herk Ventures** (sellers) in the sale of NightBalance to Royal Philips
- Advising **ViroClinics** on the acquisition of DDL Diagnostic Laboratory B.V.
- Advising **Crown Bioscience Inc** on the acquisition of Ocello B.V., biotech company offering CRO services for the drug discovery industry
- Advising the **sellers (including Forbion Capital Partners, Ysios Capital Partners, Kurma Life Science Partners, Inventages Venture Capital, IdInvest Partners, BB Biotech, Gilde Healthcare)** of AM Pharma B.V., in respect of the acquisition by Pfizer of a minority interest and exclusive option to acquire the remaining interest for up to USD 600 million
- Advising **Terumo** on the acquisition of Quirem Medical in respect of the acquisition of a minority interest and option deal and subsequent with the acquisition of the remaining shares.
- Advising management shareholders of **ViroClinics** on the sale by ParCom to Summit Capital
- Advising **DSM Venturing** in the joint venture with Fonterra named Vivici.

## Examples of our experience | Spain



### VC investments

- Advising **Grifols** on the investment on a Series A finance round in Endpoint Health Inc.
- Advising Barcelona based digital health startup **Qida** in €18M finance round led by Kibo Ventures.
- Advising Barcelona based digital health startup **Mediktor** in series B finance round led by Swiss fund MTIP

### M&A and ECM transactions

- Advising **Grifols** on the acquisition of a 26% interest in Shanghai RAAS Blood Products in exchange of the contribution by Grifols of its 45% interest in Grifols Diagnostic Solutions Inc into Shanghai RAAS Blood Products
- Advising **Grifols** on the acquisition of US medtech company Medkeeper – including further advice on its sale to Becton Dickinson (BD)
- Advising **Grifols** on the acquisition of Kiro Robotics
- Advising **Grifols** on the **acquisition** of the diagnostic division of US pharma company Hologic
- Advising **Grifols** on the acquisition of Novartis Nucleic Acid Amplification Techniques (NAT) business
- Advsing **Grifols** on the agreement with the Hong Kong's Tiancheng International Investment Ltd. to acquire 100% of the shares of Tiancheng Pharmaceutical Holdings AG, which holds approximately a stake of 89.88% of Biotest ordinary shares and 1.08% of Biotest preferred shares for approximately EUR1.1bn.
- Advsing **Grifols** on the agreement with the Hong Kong's Tiancheng International Investment Ltd. to acquire 100% of the shares of Tiancheng Pharmaceutical Holdings AG, which holds approximately a stake of 89.88% of Biotest ordinary shares and 1.08% of Biotest preferred shares for approximately EUR1.1bn.
- Advising **Grifols** on the acquisition of Green Cross Biotherapeutics, dedicated to construction of plasma fractionation facility in Montreal.
- Advising **Grifols** on the acquisition of Access Biologicals, dedicated to the collection and manufacturing of an extensive portfolio of biological products.
- Advising **Grifols** on the acquisition of 7 U.S. based plasma donation centers from KedPlasma
- Advising **Grifols** on the acquisition of 25 U.S. based plasma donation centers from BPL
- Advising **Grifols** on the USD1 Bn investment made by GIC in Grifols' subsidiary Biomat USA, Inc.
- Advising **Grifols** on the acquisition of GigaGen, a biotechnology company specialized in the early discovery and development of recombinant biotherapeutic medicines.
- Advising **Grifols** on the acquisition of Alkahest, dedicated to discovering and developing treatments for neurodegenerative and age-related diseases with transformative therapies.
- Advising **Grifols** on the sale of VCN Biociencias, S.L. to Synthetic Biologics, Inc.
- Advising **Grifols** in its acquisition of Tiancheng (Germany) Pharmaceutical Holdings, owner of 90% of the ordinary shares and 1% the preferred shares of Biotest AG and the Voluntary Tender Offer for the remaining shares of Biotest AG.
- Advising **Grifols** on the acquisition of 100% of the shares of Prometic Plasma Resources Inc.

## Examples of our experience | United Kingdom



### VC investments

- Advising **AviadoBio**, a pioneering gene therapy company, on its US\$80m Series A funding round led by NEA and EQT Life Science (formerly LSP)
- Advising **Advent Life Sciences** on its lead investment in global health technology platform, Proximie's US\$80m Series C funding
- Advising **Science Creates Ventures** on five investments, including investments into Forefront RF and CytoSeek
- Advising **Cambridge Innovation Capital/Advent** on Epitopea's multi-jurisdictional US\$13.6 million Series A funding
- Advising **Rhythm AI**, a UK spin-out from St Bartholomew's Hospital focused on the treatment of atrial fibrillation, on its seed funding round
- Advising **Inotec AMD**, a fast-growing medtech business that has developed a new device to heal complex chronic wounds, in relation to a £7m funding round
- Advising **Optellum**, a pioneering AI lung cancer diagnosis innovator spun-out of Oxford University, on its US\$14m Series A funding round
- Advising **Advent Life Sciences & Sonder Capital** on their investment in Wondr Medical's £12m seed funding round
- Advising **Amphista Therapeutics**, a leader in next generation targeted protein degradation approaches, on its US\$53m Series B funding round
- Advising **Oxular** on its £27m funding round led by Forbion Capital Partners
- Advising **Blueyard Capital** on its investment in Biofidelity Limited; Biofidelity is developing a molecular diagnostic assay, enabling the rapid detection of target DNA sequences
- Advising **Basecamp Research Ltd** on its \$20m funding
- Advising **UCL Technology Fund** on its lead investment in Bloomsbury Genetic Therapies' £5m funding round
- Advising **Albion VC** on its lead investment in Peppy Health's \$45m Series B funding round
- Advising **NeRRe Therapeutics**, a clinical-stage company developing Orvepitant its wholly-owned NK-1 antagonist, on its £20m Series B2 financing round

### M&A and ECM transactions

- Advising **BioNTech** on its £562m acquisition of AI start-up, Instadeep, its largest transaction to date
- Advising **Argonaut Therapeutics** on its merger with Celleron Therapeutics to form IngenOx Therapeutics
- Advised the selling shareholders of **The Research Partnership Limited**, a leading market insights platform to the life sciences industry, on the company's sale to Ashfield Huntsworth. Deal value undisclosed.
- Advising **Uniphar** on its acquisition of Devonshire Healthcare Services Ltd
- Advising **Lucid Group** on its acquisition of leading consulting firm, Synetic Life Sciences
- Advising the shareholders of **Fortius Group Limited** on the sale of the company, the UK's single largest orthopaedic group with an international reputation in orthopaedics and MSK, to Affidea Group, the leading European provider of diagnostic imaging, outpatient and cancer care services

# 4

## Our team



## Our wider Corporate LSH team | Contact details



### Hadrien Chef

Partner  
Belgium

T +32 2 515 9324  
[hadrien.chef@osborneclarke.com](mailto:hadrien.chef@osborneclarke.com)



### David Haex

Managing Partner  
Belgium

T +32 2 515 9322  
[david.haex@osborneclarke.com](mailto:david.haex@osborneclarke.com)



### Catherine Olive

Managing Partner  
France

T +33 184 8 24532  
[catherine.olive@osborneclarke.com](mailto:catherine.olive@osborneclarke.com)



### Florent Gurlie

Counsel  
France

T +33 1 84 8 24550  
[florent.gurlie@osborneclarke.com](mailto:florent.gurlie@osborneclarke.com)



### Martin Sundermann

Partner  
Germany

T +49 89 5434 8026  
[martin.sundermann@osborneclarke.com](mailto:martin.sundermann@osborneclarke.com)



### Giuliano Lanzavecchia

Partner  
Italy

T +39 02 5413 1773  
[giuliano.lanzavecchia@osborneclarke.com](mailto:giuliano.lanzavecchia@osborneclarke.com)



### Herke van Hulst

Partner  
Netherlands

T +31 20 70 28672  
[herke.vanhulst@osborneclarke.com](mailto:herke.vanhulst@osborneclarke.com)



### Marie-Louise Weeda

Partner  
Netherlands

T +31 20 70 28698  
[marie-louise.weeda@osborneclarke.com](mailto:marie-louise.weeda@osborneclarke.com)



### Olgierd Swierzewski

Partner  
Poland

T +48 22 152 42 12  
[olgierd.swierzewski@osborneclarke.com](mailto:olgierd.swierzewski@osborneclarke.com)



### Oscar Calsamiglia

Socio/Partner  
Spain

T +34 93 419 18 18;ext=280  
[oscar.calsamiglia@osborneclarke.com](mailto:oscar.calsamiglia@osborneclarke.com)



### Mikael Nelson

Partner  
Sweden

T +46 709 555 059  
[mikael.nelson@osborneclarke.com](mailto:mikael.nelson@osborneclarke.com)



### Matthew Edwards

Partner  
United Kingdom

T +44 207 105 7786  
[matthew.edwards@osborneclarke.com](mailto:matthew.edwards@osborneclarke.com)



### Justin Starling

Partner  
United Kingdom

T +44 118 925 2090  
[justin.starling@osborneclarke.com](mailto:justin.starling@osborneclarke.com)

## About Osborne Clarke | Global overview

### Our global connections and 'best friends'

Through a network of 'best friends' we extend our reach across the globe, particularly in North America, EMEA & Asia Pacific. We have worked closely with like-minded firms in over 100 countries. We'll find the right local partner for you and wherever that may be, we will make sure that you receive the Osborne Clarke level of service.

#### Europe

Belgium: Brussels

France: Paris

Germany: Berlin, Cologne, Hamburg, Munich

Italy: Busto Arsizio, Milan, Rome

The Netherlands: Amsterdam

Poland: Warsaw

Spain: Barcelona, Madrid, Zaragoza

Sweden: Stockholm

UK: Bristol, London, Reading

#### USA

New York, San Francisco, Miami

#### Asia

China: Shanghai

India\*: Bangalore, Mumbai, New Delhi

Singapore

Osborne Clarke is the business name for an international legal practice and its associated businesses.

Full details here: [osborneclarke.com/verein](http://osborneclarke.com/verein)

\*Services in India are provided by a relationship firm

### Osborne Clarke in numbers

1260+

talented lawyers

working with

330+

expert Partners

in

26

international locations\*

advising across

8

core sectors

with

1

client-centred approach





Osborne Clarke is the business name for an international legal practice and its associated businesses. Full details here: [osborneclarke.com/verein](https://osborneclarke.com/verein)

These materials are written and provided for general information purposes only. They are not intended and should not be used as a substitute for taking legal advice. Specific legal advice should be taken before acting on any of the topics covered.

© Osborne Clarke LLP

January 2024

Publication number: 12705581

Helping you  
succeed in  
tomorrow's  
world.